Podcasts about Moderna

If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

On today's HighWire, Former CDC Director Robert Redfield is now saying the quiet part out loud, admitting we were right about mRNA and spike protein. Also, Del Celebrates RFK Jr.'s Announcement of 21 new members of the Interagency Autism Coordinating Committee (IACC), the committee responsible for coordinating the government's autism research and response. This is huge, and Del has the details.Then, we examine Moderna's announcement that it is halting new Phase 3 vaccine trials, citing reduced market incentives under increased federal oversight. What does this decision reveal about safety testing, accountability, and public health priorities?Also, a deep dive into the UK's newly announced AI surveillance system — described by officials as a “panopticon.” We unpack the origins of the term and what it signals about the future of mass surveillance.Plus, as fraud investigations rock Minnesota, autism education providers are facing devastating funding cuts. Jennifer Larson of Holland Center joins Del to explain how legitimate, long-standing programs are now at risk — and how families are paying the price.Guest: Jennifer LarsonBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

My co-host Ken Suzan and I are welcoming you to episode 171 of our podcast IP Fridays! Today's interview guest is the president of the German Patent and Trademark Office Eva Schewior! But before we jump into this very interesting interview, I have news for you: The US Supreme Court has taken up an important patent law case concerning so-called “skinny labels” for generic drugs. Specifically, the highest US court is reviewing a case in which Amarin accuses generic drug manufacturer Hikma of inciting doctors to use the cholesterol drug Vascepa in violation of patents by providing a limited package insert. In two landmark decisions, the UPC Court of Appeal clarified the criteria for inventive step and essentially confirmed the EPO’s typical “problem-solution” approach (Amgen v Sanofi and Meril v Edwards). However, experts are not entirely sure whether the Court of Appeal’s decisions, particularly those relating to the determination of the closest prior art, deviate from EPO practice. As a result of Brexit, mutual recognition of trademark use between the EU and the UK will cease to apply from January 1, 2026. Use of a trademark only in the UK will then no longer count as use of an EU trademark for the purpose of maintaining rights – and conversely, EU use will no longer count for British trademarks. Bayer is attacking several mRNA vaccine manufacturers in the US (Pfizer, BioNTech, Moderna, and J&J separately). The core allegation: patent infringements relating to old (Monsanto) patents on mRNA stabilization; Bayer is seeking damages, not sales bans. DISCO Pharmaceuticals from Cologne signs an exclusive license agreement with Amgen (potentially up to USD 618 million plus royalties) for novel cancer therapies targeting surface structures. Relevant from an IP perspective: license scope, milestones, data/know-how allocation. And now let's jump into the interview with Eva Schewior! The German IP System in Transition: Key Insights from DPMA President Eva Schewior In an in-depth conversation on the IP Fridays podcast, Eva Schewior, President of the German Patent and Trademark Office (DPMA), outlined how Germany's IP system is responding to rising demand, technological change, and a fundamentally altered European patent landscape. The interview offers valuable insights for innovators, companies, and IP professionals navigating patent, trademark, and design protection in Europe. Sustained Demand and Procedural Efficiency Despite the introduction of the Unitary Patent system, national German IP rights continue to see strong and growing demand. According to Schewior, application numbers at the DPMA have been increasing for years, which she views as a strong vote of confidence in the quality and reliability of German IP rights. At the same time, this success creates pressure on examination capacity. The average duration of patent proceedings at the DPMA is currently around three years and two months from filing to grant, provided applicants request examination early and avoid extensions. Internationally, this timeframe remains competitive. Nevertheless, shortening procedures remains a strategic priority. Search requests alone have risen by almost 50% over the past decade, yet the DPMA still delivers search reports on time in around 90% of cases. To better reflect applicant needs, the DPMA distinguishes between two main user groups: applicants seeking a rapid grant, often as a basis for international filings, and applicants primarily interested in a fast, high-quality initial assessment through search or first examination. Future procedural adjustments are being considered to better serve both groups. The Role of Artificial Intelligence Artificial intelligence already plays a practical role at the DPMA, particularly in patent search, classification, and the translation of Asian patent literature. Schewior emphasized that the office is closely monitoring rapid developments in AI to assess where these tools can further improve efficiency. However, she made clear that AI will remain a supporting technology. In public administration, and especially in IP examination, final decisions must always be taken and reviewed by humans. AI is seen as a way to relieve examiners of routine tasks so they can focus on substantive examination and quality. Maintaining and Monitoring Examination Quality Quality assurance is a central pillar of the DPMA's work. Schewior reported consistently positive feedback from users, but stressed that maintaining quality is a continuous task. The office applies systematic double checks for grants and refusals and uses internal quality management tools to randomly review searches and first office actions during ongoing proceedings. External feedback is equally important. The DPMA's User Advisory Board, which includes patent attorneys, startups, and patent information centers, plays a key role in identifying issues and suggesting improvements. Several of its recommendations have already been implemented. Trademark Filings and Bad-Faith Applications The trademark side of the DPMA has experienced particularly strong growth. In 2025, the office received around 95,000 trademark applications, an increase of approximately 18% compared to the previous year. Much of this growth came from abroad, especially from China. While new trademark types such as sound marks, multimedia marks, and holograms have so far seen only moderate uptake, word marks and figurative marks remain dominant. A growing challenge, however, is the rise in bad-faith trademark filings. The DPMA has responded by intensively training examiners to identify and handle such cases. Procedural reforms following EU trademark law modernization have also shifted competencies. Applicants can now choose whether to bring revocation and invalidity actions before the courts or directly before the DPMA. While courts may act faster, proceedings before the DPMA involve significantly lower financial risk, as each party generally bears its own costs. Accelerated Examination as a Practical Tool Despite rising filing numbers, the DPMA aims to avoid significant delays in trademark proceedings. Organizational restructuring within the trademark department is intended to balance workloads across teams. Schewior highlighted the option of accelerated trademark examination, available for a relatively modest additional fee. In practice, this can lead to registration within a matter of weeks, without affecting priority, since the filing date remains decisive. New Protection for Geographical Indications A major recent development is the extension of EU-wide protection for geographical indications to craft and industrial products. Since late 2025, the DPMA acts as the national authority for German applications in this area. The first application has already been filed, notably for a traditional German product. Under the new system, applications undergo a national examination phase at the DPMA before being forwarded to the EUIPO for final decision. Products eligible for protection must originate from a specific region and derive their quality or reputation from that origin, with at least one production step taking place there. The EU estimates that around 40 German products may qualify. Outreach, SMEs, and Education Schewior underlined the DPMA's statutory duty to inform the public about IP rights, with a particular focus on small and medium-sized enterprises. The office has significantly expanded its presence on platforms such as LinkedIn and YouTube, offering accessible and practical IP content. Studies show that fewer than 10% of European SMEs use IP rights, despite evidence that IP-owning companies generate higher revenues. To address this gap, the DPMA is expanding outreach formats, strengthening cooperation with educational institutions, and publishing new empirical studies, including a forthcoming analysis of patenting behavior among innovative German startups conducted with WIPO. Strategic Challenges Ahead Looking forward, Schewior identified several key challenges: insufficient awareness of IP protection among SMEs and startups, a tendency in some sectors to rely solely on trade secrets, and the growing problem of product and trademark piracy linked to organized crime. From an institutional perspective, the DPMA must remain attractive and competitive in a European system offering multiple routes to protection. This requires legally robust decisions, efficient procedures, qualified staff, and continuous investment in IT and training. Careers at the DPMA Finally, Schewior highlighted recruitment as a strategic priority. The DPMA recently hired around 50 new patent examiners and continues to seek experts in fields such as electrical engineering, e-mobility, IT, and aerospace, as well as IT specialists, lawyers, and staff in many other functions. She emphasized the DPMA's role as Europe's largest national patent office and a globally significant, stable, and family-friendly employer at the forefront of technological development. German and European Patents as Complementary Options In her closing remarks, Schewior addressed the post-UPC patent landscape. Rather than competing, German and European patent systems complement each other. For many SMEs, a German patent alone may be sufficient, particularly where Germany is the core market. At the same time, the possibility of holding both a European patent and a national German patent offers strategic resilience, as national protection can survive even if a European patent is revoked. Her key message was clear: the range of options has never been broader, but making informed strategic choices is more important than ever. If you would like, I can also adapt this article for a specialist legal audience, condense it for a magazine format, or rework it as a thought-leadership piece for LinkedIn or your website. Rolf Claessen: Today's interview guest is Eva Schewior. If you don't know her yet, she is the President of the German Patent and Trademark Office. Thank you very much for being here. Eva Schewior: I'm very happy that you're having me today. Thank you, Mr. Claessen. Rolf Claessen: Shortening the length of procedures has been a stated goal since you took office. What is the current situation, and which measures are in place to achieve this goal? Eva Schewior: First of all, I'm very glad that German IP rights are in high demand. Even though applicants in Europe have multiple options today to obtain protection for their innovations, we have seen increasing application numbers for years at my office, even after the introduction of the Unitary Patent system. I see this as very positive feedback for our work. It is clear, however, that the high number of applications leads to a constantly increasing workload. At the same time, we want to remain attractive for our applicants. This means we must offer not only high-quality IP rights but also reasonable durations of proceedings. Ensuring this remains a central and permanent objective of our strategy. The average duration of proceedings from filing to grant is currently about three years and two months, provided that applicants file an examination request within the first four months after application and do not request extensions of time limits. In other cases, the average duration of proceedings is admittedly longer. With these three years and two months, we do not have to shy away from international comparison. Nonetheless, we strive to get better. In the last few years, we were able to improve the number of concluded proceedings or to keep them at a high level. In some areas, we were even able to shorten durations of proceedings a bit, though not yet to the extent that we would have wished for. Our efforts are often overtaken by the increasing demand for our services. Just to give you an example, in the last ten to fifteen years, search requests increased by nearly fifty percent. Despite this, we managed to deliver search reports in ninety percent of all cases in time, so that customers have enough time left to take a decision on a subsequent application. I have to admit that we are not equally successful with the first official communication containing the first results of our examination. Here, our applicants need a bit more patience due to longer durations of proceedings. But I think I do not have to explain to your expert audience that longer processing times depend on various reasons, which are in no way solely to be found on our side as an examination office. To further reduce the length of proceedings, we need targeted measures. To identify them, we have analyzed the needs of our applicants. It has been shown that there are two main interests in patent procedures. About three quarters of our applicants have a very strong interest in obtaining a patent. They mainly expect us to make fast decisions on their applications. Here we find applicants who want to have their invention protected within Germany but often also wish for subsequent protection outside Germany. The remaining quarter consists of applicants that are solely interested in a fast and high-quality first assessment of the application by means of a search or a first official examination. We observe that these applicants use our services before they subsequently apply outside Germany. This latter group has little interest in continuing the procedure before my office here in Germany. We are currently considering how we can act in the best interest of both groups. What I can certainly say is that we will continue to address this topic. And of course, in general, it can be said that if we want to shorten the duration of proceedings, we need motivated and highly skilled patent examiners. Therefore, we are currently recruiting many young colleagues for our offices in Munich and Jena, and we want to make our procedures more efficient by using new technical options, thus taking workload from patent examiners and enabling them to concentrate on their core tasks and on speedy examination. Rolf Claessen: Thank you very much. I also feel that the German Patent and Trademark Office has become quite popular, especially with the start of the UPC. Some applicants seem to find that it is a very clever option to also file national patents in Germany. Eva Schewior: I think you're perfectly right, and I think we will come to this point later. Rolf Claessen: In 2023, you mentioned artificial intelligence as an important tool for supporting patent examiners. What has happened regarding AI since then? Eva Schewior: Of course, we are already successfully using AI at our office. For instance, in the field of patent search, we use AI-based tools that make our examiners' work easier. We also use AI quite successfully for classification and for the translation of Asian patent literature into English. In the meantime, we have seen a rapid development of AI in the market. I think it is strategically imperative to get an overview and to make realistic assessments of what AI is capable of doing to make our procedures more efficient. Therefore, we are observing the market to find out where AI can perform tasks so that we enable examiners to concentrate on their core business. There are many ideas right now in our office where artificial intelligence can help us tackle challenges, for instance demographic change, which certainly also affects our office, and maintaining our quality standards. We will strategically promote new tools in this field to cope with these challenges. But this much is also clear: humans will always stay in our focus. Especially in public administration, I consider it a fundamental principle that in the end, decisions must be taken and reviewed by humans. AI may help us reach our goals in a more efficient way, but it can never replace patent or trademark examiners. Rolf Claessen: You have made quality improvements in patent examination a priority and have already implemented a number of measures. How would you describe the current situation? Eva Schewior: I often receive positive feedback from different sides that our users are very satisfied with the quality of our examination, and I'm very glad about that. But maintaining this quality standard is a permanent task, and we must not become careless here. For years, for instance, we have established double checks for all grants and rejections. In addition, we have introduced a quality management tool that enables us, even during the examination process, to randomly check the quality of first office communications and searches. This helps us detect critical trends and take appropriate countermeasures at a very early stage. What is also very important when it comes to patent quality is to actively ask our customers for their feedback. We do this in different ways. Just to give you an example, we have a User Advisory Board, which is a panel of external experts implemented a couple of years ago. Discussing questions of quality is regularly on the agenda of this board. We carefully listen to criticism, ideas, and suggestions, and we have already implemented some of them for the benefit of the office and our users. Rolf Claessen: The German Patent and Trademark Office, as the largest patent and trademark office in Europe, records very high numbers of trademark applications. What are you currently especially concerned with in the trademark area? Eva Schewior: In 2025, we saw around ninety-five thousand trademark applications. This is an increase of eighteen percent compared to the previous year, and I have to say that this took us by surprise. Especially applications from outside Germany, and above all from China, have risen significantly. It is of course challenging to cope with such a sudden increase on an organizational level. Another challenge is dealing with trademark applications filed in bad faith, which we are currently seeing more and more of. We have thoroughly trained our trademark examiners on how to identify and handle such applications. As regards the new types of trademarks, the rush has been moderate so far. Sound marks, multimedia marks, or holograms are apparently not yet common solutions for the majority of applicants. The key focus remains on word marks and combined word and figurative marks. Nevertheless, I believe that the new trademark types are a meaningful supplement and may play a greater role as digitization advances. The most significant changes, however, concern procedures. Applicants can now choose whether to file revocation or invalidity actions with the courts or with our office. While courts may proceed somewhat faster, the financial risk is higher. Before the DPMA, each party generally bears its own costs, apart from exceptional cases. Rolf Claessen: How does this dynamic filing development impact the duration of trademark proceedings? Eva Schewior: This is indeed a major organizational challenge. For a long time, our trademark department managed to keep durations of proceedings very short, especially with regard to registration. Despite the recent increases in applications, especially in 2025, we hope to avoid a significant extension of processing times. We have restructured the organization of the trademark department to distribute applications more equally among teams. Applicants should also be aware that it is possible to request accelerated examination for a relatively moderate fee of two hundred euros. This often leads to registration within a very short time. The filing date, of course, always determines priority. Rolf Claessen: Since December 2025, the EU grants protection not only for agricultural products but also for craft and industrial products through geographical indications. Has your office already received applications? Eva Schewior: Yes, we have received our first application, and interestingly it concerns garden gnomes. Protected geographical indications are an important topic because they help maintain traditional know-how in regions and secure local jobs. The DPMA is the competent authority for Germany. Applications go through a national examination phase at our office before being forwarded to the EUIPO, which takes the final decision on EU-wide registration. Eligible products must originate from a specific region and derive their quality, reputation, or characteristics from that origin, with at least one production step taking place there. Rolf Claessen: The DPMA has expanded its outreach activities, including social media. What else is planned? Eva Schewior: Raising awareness of IP rights, especially among small and medium-sized enterprises, is part of our statutory duty. We currently use LinkedIn and YouTube to communicate IP topics in an understandable and engaging way. We also plan dedicated LinkedIn channels, for example for SMEs. Studies show that fewer than ten percent of European SMEs use IP rights, even though those that do earn significantly more on average. In 2026, we will further expand outreach activities, cooperate more closely with universities and educational institutions, and publish new studies, including one on the patenting behavior of innovative German start-ups conducted together with WIPO. Rolf Claessen: Where do you see the biggest future challenges in IP? Eva Schewior: Germany depends on innovation, but awareness of IP protection is still insufficient, particularly among SMEs and start-ups. Some companies deliberately avoid IP rights and rely on trade secrets, which I consider risky. Another growing concern is the increase in product and trademark piracy, often linked to organized crime. For our office, remaining attractive and competitive is crucial. Applicants have many options in Europe, so we need fast procedures, legally robust decisions, qualified staff, and modern IT systems. Rolf Claessen: The DPMA is currently recruiting. Which areas are you focusing on? Eva Schewior: Our focus is on patent examination and IT. We recently hired fifty new patent examiners and are particularly looking for experts in fields such as electrical engineering, e-mobility, IT, and aerospace. We are Europe's largest national patent office and offer meaningful, secure jobs with fair compensation and strong development opportunities. Rolf Claessen: Is there a final message you would like to share with our listeners? Eva Schewior: The Unitary Patent system has created many new options. German and European patent systems do not compete; they complement each other. For many SMEs, a German patent may already be sufficient, especially where Germany is the core market. Holding both European and national patents can also be a strategic advantage. My key message is: be aware of the options, stay informed, and choose your IP strategy deliberately. Rolf Claessen: Thank you very much for being on IP Fridays. Eva Schewior: Thank you for having me. It was a pleasure.

“Climate change is the biggest health threat of our century, so we need to train clinicians for a future where it will alter disease patterns, the demand on health systems, and how care is delivered,” says Dr. Sandro Demaio, director of the WHO Asia-Pacific Centre for Environment and Health, underscoring the stakes behind the organization's first regionally-focused climate and health strategy. The five-year plan Dr. Demaio is leading aims to help governments in 38 countries with 2.2 billion people manage rising heat, extreme weather, sea-level change, air pollution and food insecurity by adapting health systems, protecting vulnerable populations, and reducing emissions from the healthcare sector itself. In this timely interview with Raise the Line host Michael Carrese, Dr. Demaio draws on his experiences in emergency medicine, global public health, pandemic response and climate policy to argue for an interconnected approach to strengthening systems and preparing a healthcare workforce to meet the heath impacts of growing environmental challenges. This is a great opportunity to learn how climate change is reshaping medicine, public health and the future of care delivery.  Mentioned in this episode: WHO Asia-Pacific Centre for Environment and Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comFind out how the future of AI could impact your retirement during Zach Abraham's free “New Year Reset” live webinar This Thursday January 29th 3:30pm Pacific. Register at KnowYourRiskPodcast.com.Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeThere's a lot more that needs to be done. Thank God we left the WHO, but they haven't left us, I'll explain...Episode links:I FULLY support the Trump Admin pulling out of the World Health Organization and was proud to see legislation I introduced five years ago during COVID come to fruition. The WHO covered up on behalf of the ChiComms and pushes a leftist globalist agenda. Defund Tyranny.WHO SAYS: “We never imposed lockdowns or vaccine passports.” ALSO WHO: “You must follow lockdowns and use vaccine passports.” The WHO pushed policies that controlled movement and daily life, then denied it. People are NOT buying it.Bruce Alyward, senior advisor to the Director General of the World Health Organisation, pretends to not hear the question when asked if WHO would reconsider Taiwan's membership. Interviewer asks again and he shuts down meeting."We cannot afford to trust the WHO anymore." - Dr. Wahome Ngare from Kenya exposes a World Health Organization sterilization effort disguised as a vaccination campaign.BREAKING: New Study Reveals WHY Regulators Missed the DNA Contamination in mRNA Vaccinesl The answer was hiding in plain sight—and it explains everything.The CEO of Moderna says he is deeply disappointed that the company's vaccines for children are no longer being recommended. He openly confesses that the decline in demand has hurt the vaccine business. He says Moderna no longer expects to invest in new Phase 3 vaccine studies anytime soon because it no longer has access to the U.S. market.

A typical vaccine stimulates a person's immune system, yet only a portion of the immune response actually targets the disease it's designed to protect against. However, a new technology may be changing that dynamic.In this episode, I sit down with Lou Reese, an entrepreneur who has led or co-founded several biotech companies and has been working on synthetic peptide-based active immunotherapy medicines. He's co-CEO of United Biomedical and co-founder of Vaxxinity, Cana Life, and Axxium.He's working on a product that could—if proven successful—transform our approach to treating and preventing Alzheimer's. He and his team also have a product that has shown preliminary promise in phase 1 trials in treating Parkinson's.In this episode, he also reveals an incredible story: He and his team previously developed a peptide-based active immunotherapy vaccine candidate for COVID-19, and they successfully completed Phase 1 and Phase 2 trials. Institutional backing, however, favored Pfizer and Moderna. In 2022, Lou Reese's team was invited to the White House “Summit on the Future of COVID‑19 Vaccines,” where they presented their candidate as an alternative to Pfizer's mRNA vaccine, which by then had been associated with serious side effects.In the end, their product was never approved, and related content on YouTube was marked as misinformation.Views expressed in this video are opinions of the host and the guest, and do not necessarily reflect the views of The Epoch Times.

Trial results from Moderna's (MRNA) melanoma drug sent shares of the healthcare giant soaring throughout the week, though Charles Schwab's Rachel Dashiell sees that strength subsiding for now. She points to bearish trends taking control of the stock and notes key levels to watch for a potential reversal. ======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Markets digest another earnings-heavy session with Seema Mody recapping the day and Pippa Stevens tracking a commodities rally led by fresh gains in natural gas. HSBC's Max Kettner weighs in on broader market positioning and global risk, before Kristina Partsinevelos and Morgan Brennan break down key earnings from Intel and Alcoa, setting the tone for cyclicals and industrials. Jay Goldberg of Seaport reacts to Intel's results after upgrading the stock into the print. Alcoa CEO William Oplinger discusses results and outlook, followed by a look at the soaring stock of Moderna. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We have a special episode of Raise the Line on tap today featuring the debut of host Dr. Parsa Mohri, who will now be leading our NextGen Journeys series that highlights the fresh perspectives of learners and early career healthcare professionals around the world on education, medicine, and the future of care. Parsa was himself a NextGen guest in 2024 as a medical student at Acibadem University in Turkey. He's now a general physician working in the Adult Palliative Care Department at Şişli Etfal Research and Training Hospital in Istanbul.  Luckily for us, he's also continuing in his role as a Regional Lead for the Osmosis Health Leadership Initiative (OHLI). For his first guest, Parsa reached out to a former colleague in the Osmosis family, Negeen Farsio, who worked with him as a member of OHLI's predecessor organization, the Osmosis Medical Education Fellowship. Negeen is now a graduate student in medical anthropology at Brunel University of London, a degree which she hopes will inform her future work as a clinician. “Medical anthropology is a field that looks at healthcare systems and how human culture shapes the way we view different illnesses, diseases, and treatments and helps you to see the full picture of each patient.” You are sure to enjoy this heartfelt conversation on how Negeen's lived experience as a patient and caregiver have shaped her commitment to mental health and patient advocacy, and how she hopes to marry humanity with medicine in a world that yearns to heal. If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über den schlechtesten Tag an der Wallstreet seit dem Liberation Day, neue Netflix-Zahlen und jede Menge Pharma-Schlagzeilen. Außerdem geht es um Norwegian Cruise Line Holdings, Royal Caribbean, Netflix, Warner Brothers Discovery, Fresenius Medical Care, Carl Zeiss Meditec, Fresenius, Novavax, Pfizer, Moderna, Merck, GSK, ⁠RAPT Therapeutics, Qiagen, 3M und Disney. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Today marks one year since President Trump began his second term. In just one year, we've seen seismic shifts in America's foreign policy, such as his relentless bid for Greenland. Plus, he's now threatening an additional 200% tariffs on French wine if Macron refuses to join his Gaza Board of Peace. Democratic Senator Chris Coons wants to de-escalate tensions and has just finished a bipartisan congressional visit to Denmark. He joins the show from Davos.  Also on today's show: CNN Jerusalem correspondent Jeremy Diamond; NYT columnist Lydia Polgreen; Noubar Afeyan, Co-founder, Moderna    Learn more about your ad choices. Visit podcastchoices.com/adchoices

Intelligence Notes:LAWSUIT: Genomic Warfare Confirmed-Monsanto Technology in your COVID SHOTS 2026- New World Order.Pharmaceutical Warfare: Bayer, ModeRNA, Pfizer et al.To support the [Show] and its [Research] with Donations, please send all funds and gifts to :$aigner2019 (cashapp) or https://www.paypal.me/Aigner2019 or Zelle (1-617-821-3168). Shalom Aleikhem!

New research is transforming the outlook for cervical and uterine cancers -- two of the most serious gynecologic malignancies worldwide – and we'll be hearing from one of the people shaping that progress, Dr. Mary McCormack, on this episode of Raise the Line. From her perch as the senior clinical oncologist for gynecological cancer at University College London Hospitals, Dr. McCormack has been a driving force in clinical research in the field, most notably as leader of the influential INTERLACE study, which changed global practice in the treatment of locally advanced cervical cancer, a key reason she was named to Time Magazine's 2025 list of the 100 most influential people in health. “In general, the protocol has been well received and it was adopted into the National Comprehensive Cancer Network guidelines which is a really big deal because lots of centers, particularly in South and Central America and Southeast Asia, follow the NCCN's lead.”In this conversation with host Michael Carrese, you'll learn about how Dr. McCormack overcame recruitment and funding challenges, the need for greater access to and affordability of treatments, and what lies ahead for women's cancer treatment worldwide. Mentioned in this episode:INTERLACE Cervical Cancer Trial If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Ander Tallet, co-founder and COO of Dash Bio and CEO of DigitalRadius, joins Ross Katz to discuss transforming the traditional CRO model through automation, transparency, and productization. Drawing on deep experience from Moderna, Science Exchange, and his leadership roles in digital transformation, Ander shares how Dash Bio is slashing turnaround times, improving data quality, and simplifying procurement for biotech companies. This episode unpacks the future of CRO services, strategic procurement, and the power of operational innovation in biotech. What you'll learn in this episode: >> Why traditional CRO models hinder speed and transparency in biotech >> How Dash Bio delivers 90% faster turnaround through automation >> What productizing CRO services really means for the customer experience >> How regulatory requirements shape innovation in clinical bioanalysis >> Why investor buy-in requires solving real, painful problems in biotech Meet our guest Ander Tallett is the co-founder and COO of Dash Bio and the CEO of DigitalRadius, where he leads digital transformation initiatives as one of the largest Smartsheet partners in the ecosystem. He previously served as Chief Strategy Officer at Science Exchange and co-founded Block Mill Capital, a B2B SaaS-focused investment fund shaped by his experience evaluating and implementing more than 100 SaaS platforms.  About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guest: Sponsor: CorrDyn, a data consultancyConnect with Ander Tallet on LinkedIn  Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Ven al primer directo del podcast en Madrid, entradas a la venta aquí: https://entradas.grupomarquina.es/grupomarquina/events/50528?sessionView=LIST En este episodio del podcast, hablamos con Jorge Darek sobre nutrición natural, salud real y los hábitos modernos que están afectando silenciosamente a nuestro bienestar. A lo largo de la entrevista, Jorge cuestiona muchas creencias aceptadas sobre alimentación saludable, rutinas diarias, productos ultraprocesados y el estilo de vida actual, poniendo el foco en un enemigo común: el estrés crónico y la desconexión con lo natural.Si te interesa mejorar tu salud, recuperar energía, romper dogmas y entender la nutrición desde una perspectiva más natural y realista, este episodio es para ti.

Enterprise AI adoption is still stuck in the teens and the gap between the hype and the reality is getting harder to ignore. People are finding pockets of productivity, but they're often keeping the gains to themselves, worried that “using AI well” is just speed-running their way into a layoff. Meanwhile, many leaders treat it like another piece of software without touching the messier truth: AI changes how work actually happens, and it doesn't care about your org chart, your approval chains, or your performance theater. In this episode, Rodney sits down with Section CEO Greg Shove to name what's really blocking adoption and what it takes to break through. They talk about AI as “co-intelligence”, why most “AI layoffs” are PR cover, and the non-negotiables for real transformation. They also get into how to build a robust AI strategy for 2026, Section's own AI disruption, and why the next era may be dominated by super companies built around small human teams + a fleet of agents. Learn more about Greg: His website Section's website Prof.AI AI Truth Serum podcast -------------------------------- Ready to change your organization? ⁠⁠⁠⁠⁠⁠Let's talk.⁠⁠⁠⁠⁠⁠ Get our newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.⁠⁠⁠⁠⁠⁠ Follow us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ -------------------------------- Mentioned references: Edelman's AI creators Chegg's downfall Moderna's AI usage Zapier's AI usage BOX's AI usage Dual Transformation Skunk Works Mary Barra "amazon.bomb" Stanford AI study 00:00 Intro + Check-In: What's something happening in the AI hype cycle that drives you nuts right now? 03:21 Enterprise AI adoption stall out 08:58 AI as truth serum for lies in your company 11:49 Required ingredients for real AI transformation 19:04 Balancing risk with AI usage in startups and large enterprise 24:10 “Head of AI” roles are an uphill battle 27:48 First principles for an AI-lead organization 30:10 Disrupting your business model with AI and dual transformation 35:29 Greg and Section disrupting themselves with AI 37:44 Role of leadership in an AI future 44:40 Future of companies and careers 47:54 Role of companies in future of society 52:07 Wrap up: Leave us a review and share the show with a coworker! Sound engineering and design by Taylor Marvin of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Coupe Studios⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

En este episodio retomamos la conversación con Rodrigo Castilla de Citrus Patrimonial para analizar qué ha pasado después del primer capítulo: crecimiento de inversionistas, evolución del precio del limón, expansión internacional y los retos reales de escalar un negocio del campo.Hablamos de invertir en producción, no en activos financieros tradicionales; de rendimientos ligados al mercado real; de exportación, logística, fideicomisos, visión de largo plazo y por qué el campo exige paciencia, estrategia y ejecución impecable. Un episodio para entender cómo se construye un negocio sólido cuando los resultados no llegan mañana… pero pueden durar generaciones.

“The world is a very volatile place, with currently 110 conflicts globally, and yet healthcare staff in the hospitals, even here in London, are not prepared to be the only clinician who can help in a crisis or hostile setting,” says Dr. David Gough, CEO of the David Nott Foundation, which equips providers with the skills and confidence needed to function in war and other extraordinary situations. A former British Army doctor injured in Afghanistan, Gough brings lived experience as well as a background in tech to his current role at the Foundation, which itself is anchored in decades of field work amassed by its namesake, a renowned war surgeon. As Dr. Gough points out to host Lindsey Smith, the cause could be helped by augmenting medical school curricula, but in the meantime, the Foundation is filling the knowledge gap by using prosthetics, virtual reality simulations and cadavers to train a broad swath of health workers including surgeons, anesthetists, and obstetricians. Tune in to this important Raise the Line conversation as Dr. Gough reflects on the strengths and weaknesses of NGOs in doing this work, his plans to expand the Foundation's footprint in the US, and the gratifying feedback he's received from trainees now operating on the frontlines in Ukraine and elsewhere. Mentioned in this episode:David Nott Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

En este episodio me senté con Johnny Abraham para hablar sin rodeos sobre el amor moderno, la soltería, los roles en pareja, el dinero y por qué cada vez es más difícil construir relaciones duraderas.Platicamos sobre la lucha de poder entre hombres y mujeres, el miedo al compromiso, la obsesión por evitar el proceso, el impacto de las apps de citas y cómo muchas decisiones se están tomando desde la herida, no desde la elección consciente. Un episodio para cuestionar si estamos buscando equipo… o solo comodidad, y por qué el equilibrio, la comunicación y la responsabilidad siguen siendo clave para una relación sana.

Recibe tu curso gratis aquí: https://www.hombrealfa.top/curso-gratis/ Únete a los miles de hombres que forman parte de mi comunidad de email para acceder a promociones exclusivas y enterarte de la apertura de mis formaciones. Estar suscrito tiene premio y es la única manera de estar al día de las novedades del proyecto. Al suscribirte con tu email, recibes el curso gratis de «Cómo ser un hombre más atractivo e interesante para las mujeres en la era de las apps y las redes sociales». Es un curso de siete lecciones por escrito (no vídeo, no audio) que puedes personalizar en función del momento que estés viviendo en tus relaciones. Para unirte a mi comunidad y recibir el curso, deja tu email en el enlace: https://www.hombrealfa.top/curso-gratis/ *¿Qué aprenderás en este episodio?: 1) Por qué culpar al apego o al narcisismo es el nuevo ""tengo metabolismo lento"". 2) La verdadera historia de la teoría del apego y lo que de verdad intentaba explicar. 3) Por qué las etiquetas de Instagram NO explican tu fracaso relacional (aunque suenen bonito). 4) El gran error de pensar que tu estilo de apego determina tu atracción o éxito con las mujeres. 5) La razón por la que te aferras a relaciones mediocres… y la biología que lo explica mejor que cualquier test de apego. En el Episodio de hoy desmontamos la creencia más extendida (y equivocada) de la psicología pop moderna: que tu estilo de apego determina por qué tus relaciones fracasan. Analizamos su origen clínico real, lo que Bowlby y Ainsworth realmente investigaban y cómo se ha pervertido el mensaje original para justificar dinámicas desequilibradas Además, veremos por qué pensar que “soy ansioso” o “ella es evitativa” es una anestesia narrativa que te aleja de ver la raíz real del problema: una dinámica de poder, valor y escasez en la que la biología tiene mucho más que decir que cualquier etiqueta emocional. PD. Recibe tu curso gratis aquí: https://www.hombrealfa.top/curso-gratis/

Dos formaciones del pianista brasileño Benjamim Taubkin en su sello Núcleo Contemporáneo: Moderna Tradição ('Lamentos' de Pixinguinha y 'Lamentos do morro' de Garoto) y Orquestra Popular de Câmara ('Bayati' y 'Correnteza' -ambas con la voz de Mònica Salmaso- y 'Choro moreno'). Del disco que Mônica grabó con su nombre en 1999, 'Voadeira', las canciones 'Dançapé', 'Valsinha' de Vinicius de Moraes y Chico Buarque y 'Ave Maria no morro' de Herivelto Martins y, de 'Canto sedutor', que firmó en 2022 con Dori Caymmi, 'Desenredo'. Escuchar audio

2011 utbryter panik i den internationella konstvärlden. Wolfgang Beltracchi har under fyra decennier målat och sålt förfalskningar för hundratals miljoner kronor. Lyssna på alla avsnitt i Sveriges Radios app. På 90-talet dyker det upp försvunna tavlor av de världsberömda konstnärerna Max Ernst och Heinrich Campendonk. Verk som ska ha funnits, men som ingen har sett på 100 år. I själva verket är det konstnären Wolfgang Beltracchi som målat tavlorna. Han har hittat ett slags blind fläck på konstmarknaden genom att gå igenom mängder av konstkataloger. Adolf Hitler gillade inte modern konst och under naziregimen försvann tusentals verk. Och det är dom här verken som Wolfgang Beltracchi målar, som om de vore de äkta tavlorna. I nära 40 år kan Wolfgang tjäna mångmiljonbelopp på sina förfalskningar. Men en dag tar det stopp. Moderna museet lurades år 2008Wolfgang Beltracchis förfalskningar visas upp världen över – till och med i Sverige. För första gången kommenterar Moderna museet i Stockholm det faktum att de ovetandes ställde ut en av Wolfgang Beltracchi målad Max Ernst-tavla. Medverkande:Wolfgang Beltracchi, konstnären som målat förfalskningarna.Helena Beltracchi, Wolfgangs hustru och medhjälpare i förfalskningarna. Iris Müller Westermann, senior curator på Moderna Museet i Stockholm.Thomas Seydoux, tidigare senior konstexpert på auktionshuset Christie's i London.Sofia Komarova, driver galleriet Artvera's i Geneve i Schweiz.René Allonge, poliskommissarie som leder specialenheten för konstbrottslighet i Berlin.Nicolas Eastaugh, konstanalytiker och grundare av det globala konstananalyscentret VersariK.En dokumentär av Alexandra SannemalmProducent: Hannah EngbergExekutiv producent på Sveriges radio: Tove PalénDokumentären är producerad 2025.

Filho de britânicos, Derek Prince nasceu em 1915, na Índia. Estudou Filosofia Antiga e Moderna no Kings College, além de línguas, como hebraico e aramaico, na Universidade de Cambridge e na Universidade Hebraica de Jerusalém. Em julho de 1941, Derek teve o que ele descreveu como uma “experiência sobrenatural”, um encontro com Jesus que o levou à seguinte declaração: “Eu formei duas conclusões:primeiro, que Jesus Cristo está vivo; em segundo lugar, que a Bíblia é um verdadeiro, e relevante, Livro atualizado. Estas conclusões alteraram todo o curso da minha vida”.Ele é autor de mais de 50 livros, de 600 mensagens em áudio e em vídeo e 100ensinamentos muitos dos quais foram traduzidos e publicados em mais de 100idiomas. Prince faleceu, em 24 de setembro de 2003, devido a uma insuficiênciacardíaca, enquanto dormia em sua casa, em Jerusalém.

Nuestro espacio musical semanal, "El ritmo continúa", lanza un guiño en su última edición de 2025 a algunos de los pioneros leoneses que, hace alrededor de seis décadas, empezaron a importar y desarrollar en nuestra provincia los sonidos propios de la música moderna que ya imperaban en la escena internacional. Bajo esa premisa Kike Cardiaco recupera clásicos del repertorio de Los Tricolores, The Rolls y Roberto Lana.

Organiza tu trabajo y aymenta tu productividad con Odoo

AI is transforming how work happens and redefining what it means to lead. Moderna's Tracey Franklin, chief people and digital technology officer, and Heidrick & Struggles' Katie Graham Shannon, global head of the Digital and Technology Officers Practice, discuss how organizations are uniting people, technology and strategy to build new capabilities, foster innovation, and unlock enterprise value. They share how forward-looking leaders are reimagining roles, empowering teams and shaping a more connected and adaptive future workforce.

In this conversation, Heidi Harris interviews Kayla Pollock, who shares her harrowing experience of being injured by the COVID-19 vaccine. Kayla recounts her active life before the vaccine, the decision to get vaccinated under pressure, and the devastating side effects that led to her quadriplegia. She discusses her hospital experiences, misdiagnoses, and the challenges of navigating the healthcare system in Canada. The conversation also touches on the legal actions Kayla is pursuing for compensation and the disturbing trend of medical assistance in dying being offered to patients in similar situations. In this conversation, the speaker shares her harrowing journey through vaccine injury, the challenges of navigating dependency on social support systems, and the emotional toll of considering medical assistance in dying. She discusses the importance of sharing her story publicly, the gaslighting experienced from those who have been vaccinated, and the ongoing legal battle against vaccine manufacturers. The conversation highlights the duty of care and transparency that medical manufacturers owe to patients, as well as the profound impact of these experiences on family life and personal growth.To donate to her Kayla: www.opkayla.ca/donateFind Kayla: @KCpollockHer website: https://www.opkayla.caMy podcast is now on Spotify! Just search “Heidi Harris Show” and check it out!Get on my email list: Go to HeidiHarrisShow.com and click on “message the show”! The audio version of my book “Don't Pat me on the Head!” is now available at heidiharrisshow.com! HeidiHarris.comHeidiHarrisShow.comHeidi@HeidiHarris.comPodcast: Heidi Harris Show (Spotify, or anywhere you get podcasts) @HeidiHarrisShowInstagram: Heidi Harris ShowRumble: Heidi Harris Show (videos)Youtube: Heidi Harris ShowBooks: Don't Pat me on the Head! Blowback, Setbacks and Comebacks in Vegas radiohttps://www.amazon.com/Dont-Pat-Me-Head-Comebacks/dp/1984195263/ref=sr_1_1?crid=3QWT1L4CYAGUH&keywords=dont+pat+me+on+the+head&qid=1698428860&s=books&sprefix=dont+pat+me+on+the+head%2Cstripbooks%2C175&sr=1-1Cocktail Waitress Wisdom; Life Lessons Learned While Carrying a Tray in Las Vegashttps://www.amazon.com/Cocktail-Waitress-Wisdom-lessons-carrying/dp/0982983506/ref=sr_1_1?crid=XFT6XYR0G752&keywords=cocktail+waitress+wisdom&qid=1698428901&s=books&sprefix=cocktail+waitresss+wisdom%2Cstripbooks%2C169&sr=1-1

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here! Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeJenner Furst, director of the latest Angel Studios documentary "Thank You Dr. Fauci" joins the show.Episode Links:Thank You Dr. Fauci | Now Streaming | AngelBREAKING/URGENT: mRNA COVID VACCINES KILLED AT LEAST 10 KIDS, THE FDA REPORTS; An FDA review found the shots to blame for the deaths, FDA's new vaccine chief - Dr. Vinay Prasad - told staffers in an email. The agency will tighten standards on new vaccine approval, Prasad wrote.Fauci's Ebola stuntURGENT: mRNA Covid jabs should NEVER have been approved for children or young adults Pfizer, Moderna, the Biden Administration, and everyone in public health who pushed these for kids and teens have blood on their handsUnmask The Truth | Official Clip | Thank You, Dr. Fauci

Paypal: https://www.paypal.com/paypalme/editorialtpv El día de hoy hablaremos sobre el capítulo 5 del libro The Oxford Handbook of Christmas, titulado “The Twentieth and Twenty-First Centuries,” por Christopher Ferguson. Ver aquí: https://global.oup.com/academic/product/the-oxford-handbook-of-christmas-9780198831464?cc=gb&lang=en& Articulo: https://semperreformandaperu.org/2025/12/22/mas-alla-de-los-villancicos-la-sorprendente-y-conflictiva-historia-moderna-de-la-navidad/ Video: https://youtu.be/fr4VlvtXJSc  PPT: https://semperreformandaperu.org/wp-content/uploads/2025/12/navidad_un_espectro_de_historias.pdf  La Navidad del siglo XX no fue solo una fiesta: fue un escenario global donde se cruzaron imperios, migraciones, guerras, medios masivos y, sobre todo, una tensión persistente entre “Navidad cultural” y “Navidad cristiana”. En este episodio, siguiendo el capítulo de Christopher Ferguson, rastreamos cómo el festejo se expandió “alrededor del mundo” de un modo sin precedentes: llevado por colonos, misioneros, comercio y, más tarde, por radio, cine, televisión y la web.   Pero la globalización no fue homogénea. La Navidad se nacionalizó (con “estilos” ingleses o alemanes) y luego se estandarizó en parte por la influencia económica y mediática de Estados Unidos, desde luces eléctricas hasta una imagen internacional cada vez más uniforme de Santa. En paralelo, la política la instrumentalizó: desde la propaganda de regímenes totalitarios hasta el uso simbólico de árboles y villancicos en contextos de Guerra Fría; y la guerra la marcó con escenas inolvidables, como la determinación de celebrar en trincheras, campos de prisioneros o ciudades bombardeadas.   También miramos conflictos más íntimos: la ansiedad por la secularización, el peso de la logística navideña en los hogares, y la obsesión moderna por una “Navidad auténtica” que, paradójicamente, cambia cada década. Si quieres entender por qué la Navidad moderna es tan amada como disputada, aquí está la clave histórica. 

Fue todo un icono del cuplé, de la cultura y de la sofisticación. Hoy traemos a nuestro cronovisor la figura de la Fornarina. Jesús Callejo nos hablará de todos sus secretos. Luego viajamos a Córdoba para visitar la exposición El despertar a la vida, en donde se nos describe cómo era la vida de los niños y niñas en el antiguo Egipto. Lo hacemos con una de sus comisarias, la egiptóloga Esther Pons. Miguel Lázaro nos trae una nueva sección de Discos con historia de la mano de Led Zeppelin. Acabamos el programa en la guerra de Vietnam con David López Cabia, quien acaba de publicar Callejones sin gloria en donde se nos cuenta la historia de la batalla de Hue

Paypal: https://www.paypal.com/paypalme/editorialtpv El día de hoy hablaremos sobre el capítulo 4 del libro The Oxford Handbook of Christmas, titulado “The Nineteenth Century,” por Timothy Larsen. Ver aquí: https://global.oup.com/academic/product/the-oxford-handbook-of-christmas-9780198831464?cc=gb&lang=en& Articulo: https://semperreformandaperu.org/2025/12/19/como-el-siglo-xix-realmente-invento-la-navidad/ Video: https://youtu.be/LpY9bkOnO78  PPT: https://semperreformandaperu.org/wp-content/uploads/2025/12/navidad_el_rio_de_cuatro_corrientes.pdf  ¿De verdad la Navidad estaba muriendo antes de 1843 y Charles Dickens la resucitó? Este episodio entra en el siglo XIX para poner esa historia contra la evidencia. A partir del capítulo “The Nineteenth Century”, seguimos cómo la Navidad ya era una festividad importante en Inglaterra en las primeras décadas del siglo, y cómo ciertos argumentos “clásicos” (por ejemplo, el supuesto silencio anual de The Times) se desmoronan al revisar los datos y el contexto editorial de la época.   Luego examinamos lo que sí cambió: la expansión y reconfiguración de la fiesta en clave victoriana. La Navidad se volvió más amplia y más densa: crecieron sus marcas domésticas (familia, infancia, regalos, árbol), su infraestructura cultural (villancicos, decoración, tarjetas), y su dimensión moral (caridad y responsabilidad social en un mundo industrial).   El capítulo también muestra un giro poco reconocido: la progresiva aceptación de la Navidad por parte de protestantes reformados y disidentes, que antes la rechazaban como “no bíblica”, pero terminaron incorporándola —a veces por la presión social, a veces por dinámicas de ministerio infantil y escuela dominical.   Finalmente, rastreamos dos símbolos decisivos: Santa Claus y el árbol, ambos difundidos en gran medida por redes cristianas y por tradiciones protestantes alemanas. La Navidad moderna no nació de la nada: fue una transformación acumulativa. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements, revealing a landscape rich with scientific innovation and strategic maneuvers poised to impact patient care and the drug development pipeline.Let's start with Johnson & Johnson's recent FDA approval for a subcutaneous version of Rybrevant, their lung cancer medication. This new formulation offers a more convenient administration method compared to AstraZeneca's Tagrisso, intensifying competition in the non-small cell lung cancer market. The shift towards more patient-friendly delivery systems underscores the industry's commitment to enhancing treatment adherence and convenience. In contrast, Insmed faced a setback with its phase 2 trial for Brinsupri in treating chronic rhinosinusitis without nasal polyps. The discontinuation of this program highlights the unpredictable nature of clinical trials and emphasizes the need for rigorous scientific validation before advancing therapeutic candidates.Meanwhile, Lilly has shown promising results with its oral obesity pill, marking significant progress in weight management therapies. Patients transitioning from injectable GLP-1 therapies to Lilly's oral drug candidate maintained substantial weight loss, positioning Lilly favorably against Novo Nordisk's Wegovy. The potential for oral formulations to revolutionize treatment paradigms in chronic conditions cannot be understated. Lilly's progress in obesity treatment with its oral medication orforglipron further cements its competitive edge. Participants in their Phase III clinical trial maintained weight loss after switching from Wegovy or Zepbound to orforglipron, suggesting an efficacious oral alternative to injectable treatments and potentially enhancing patient adherence.On the regulatory front, the Biosecure Act's progression within a major defense spending bill could impose new challenges for life sciences companies with Chinese affiliations. This legislative shift reflects geopolitical tensions impacting global pharmaceutical collaborations and underscores the importance of regulatory compliance in international partnerships. Similarly, Intercept Pharmaceuticals' restructuring following the withdrawal of Ocaliva from the U.S. market is indicative of strategic pivots in response to regulatory hurdles and evolving market dynamics.In dermatology, Takeda's successful phase 3 trials for Zasocitinib highlight the competitive nature of drug development as multiple players vie for market share within therapeutic areas. Their anticipated 2026 FDA filing underscores the prolonged timelines involved in bringing novel therapies to market despite successful clinical outcomes.Public-private collaborations continue to play a crucial role in vaccine development, as evidenced by Moderna's pandemic influenza vaccine advancement into phase 3 trials with support from the Coalition for Epidemic Preparedness Innovations (CEPI). This $54 million investment illustrates ongoing efforts to bolster pandemic preparedness through innovative mRNA technologies. Meanwhile, Moderna's $54 million funding from CEPI to advance its bird flu vaccine highlights resilience amidst fluctuating governmental support. This endeavor leverages Moderna's mRNA technology platform, emphasizing mRNA's versatility across various infectious diseases.Shifting our focus slightly, medical groups have expressed opposition to changes in hepatitis B vaccination recommendations by the CDC for newborns. Such policy debates have significant implications for public health strategies and highlight ongoing discussions within medical communities regarding optimal vaccination protocols.GSK's strategic collaboration with Camp4 Therapeutics marks another key industry development. With an investment exceeding $400 million, GSK aims to Support the show

“People are not looking for a perfect, polished answer. They're looking for a human to speak to them like a human,” says Jessica Malaty Rivera, an infectious disease epidemiologist and one of the most trusted science communicators in the U.S. to emerge from the COVID-19 pandemic. That philosophy explains her relatable, judgement-free approach to communications which aims to make science more human, more accessible and less institutional. In this wide-ranging Raise the Line discussion, host Lindsey Smith taps Rivera's expertise on how to elevate science understanding, build public trust, and equip people to recognize disinformation. She is also keen to help people understand the nuances of misinformation -- which she is careful to define – and the emotional drivers behind it in order to contain the “infodemics” that complicate battling epidemics and other public health threats. It's a thoughtful call to educate the general public about the science of information as well as the science behind medicine. Tune in for Rivera's take on the promise and peril of AI-generated content, why clinicians should see communication as part of their professional responsibility, and how to prepare children to navigate an increasingly complex information ecosystem.Mentioned in this episode:de Beaumont Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Philipp Vetter über ein Ausnahmejahr für Rückversicherer, einen Dämpfer für Rüstungsaktien und Enttäuschung bei Pfizer. Außerdem geht es um Rheinmetall, Renk, Hensoldt, Lufthansa, Easyjet, Warner Bros Discovery, Paramount Skydance, Netflix Pfizer, Moderna, Biontech, Tilray Brands, Swiss Re, Munich Re, Hannover Rück, iShares S&P 500 Insurance ETF (WKN: A0H08K), Rize USA Environmental Impact UCITS ETF (WKN: A3ENMA), iShares MSCI Climate Transition Aware UCITS ETF (WKN: 906866), Lyxor MSCI Green Infrastructure ETF (WKN: LYX0YL), VanEck Sustainable Infrastructure ETF (WKN: A12HWR), Teva Pharmaceutical, Bank Leumi, Bank Hapoalim, Elbit Systems und Check Point Software. Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Si la Biblia es la Palabra de Dios, ¿por qué no menciona temas científicos modernos como la capa de ozono, la genética, el calentamiento global o la posibilidad de vida extraterrestre?En este episodio explicamos qué es la Biblia, cuál es su propósito real y por qué no debemos esperar que responda preguntas científicas contemporáneas. También exploramos la relación entre revelación divina, ciencia y adoración.Envía tus preguntas a: preguntas@verdadyfe.comConecta con nosotros aquí: https://linktr.ee/verdadyfe

✨ Apoya nuestro podcast y disfruta sin interrupciones ✨ Si valoras nuestro contenido, ayúdanos a seguir creando más episodios y, como agradecimiento, escucha Estoicismo Filosofía Premium sin anuncios.

Algunas producciones de la etiqueta norteamericana Víctor, editadas en la frontera de los años 30 a los 40 del siglo XX, nos permitirán revivir el fenómeno de la "cubanización" de las orquestas jazz bands. La orquesta Hermanos Castro con su cantante Miguelito García, Miguelito Valdés con la Casino de la Playa, Cascarita con la orquesta Hermanos Palau y Reinaldo Valdés "el jabao" con la orquesta del trompetista Julio Cueva nos acercan algunos clásicos de la música popular cubana. A continuación, y a propósito de la evolución de los jazz bands en la isla, un recuerdo para uno de los grandes artífices de este formato orquestal: el pianista, arreglista y compositor Ernesto Duarte. Fernando González, Tata Ramos y Rolo Martinez, grabados y producidos por el talentoso músico para su etiqueta "Duarte" llegan con la sonoridad del jazz band de los últimos años 50. Junto al contrabajista Cachao López y otros notables instrumentistas como Alejandro "el negro" Vivar en trompeta, Generoso "Tojo" Jiménez en trombón, Rogelio "Yeyito" Iglesias en los bongoes, Guillermo Barreto en pailas, Niño Rivera en el tres, Tata Güines en las tumbadoras, volvemos a los míticos estudios de Panart y a las "descargas en miniatura" que, finalizando los 50, permitieron cristalizar la categoría del jazz en el panorama discográfico cubano. En ese sentido las producciones "Tropicana", propiciadas por el genio de la emisora CMOX: Adolfo Seeman, constituyeron un paso más en el desarrollo en la discografia en función de darle más consistencia a la llamada "descarga". Frank Emilio a la cabeza del "Quinteto de Música Moderna", impulsado comercialmente por Seeman, con la complicidad de Papito Hernández en contrabajo, Gustavo Tamayo en güiro, Tata Güines en las tumbadoras y Guillermo Barreto en drum y pailas. En la despedida, y de vuelta al catálogo RCA Víctor, revisitamos el debut discográfico del Benny Moré como parte del conjunto Matamoros. Las maravillas de la música popular cubana, todos los domingos, las reservamos aquí para ti.

“Delivering a baby one day and holding a patient's hand at the end of life literally the next day...that continuity is very powerful,” says Dr. Jen Brull, board chair of the American Academy of Family Physicians (AAFP). And as she points out, that continuity also builds trust with patients, an increasingly valuable commodity when faith in medicine and science is declining. As you might expect given her role, Dr. Brull believes strengthening family medicine is the key to improving health and healthcare. Exactly how to do that is at the heart of her conversation with host Lindsey Smith on this episode of Raise the Line, which covers ideas for payment reform, reducing administrative burdens, and stronger support for physician well-being. And with a projected shortage of nearly forty thousand primary care physicians, Dr. Brull also shares details on AAFP's “Be There First” initiative which is designed to attract service-minded medical students – whom she describes as family physicians at heart -- early in their educational journey. “I have great hope that increasing the number of these service-first medical students will fill part of this gap.”Tune-in for an informative look at a cornerstone of the healthcare system and what it means to communities of all sizes throughout the nation.  Mentioned in this episode:AAFP If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Recibe tu curso gratis aquí: https://www.hombrealfa.top/curso-gratis/ Únete a los miles de hombres que forman parte de mi comunidad de email para acceder a promociones exclusivas y enterarte de la apertura de mis formaciones. Estar suscrito tiene premio y es la única manera de estar al día de las novedades del proyecto. Al suscribirte con tu email, recibes el curso gratis de «Cómo ser un hombre más atractivo e interesante para las mujeres en la era de las apps y las redes sociales». Es un curso de siete lecciones por escrito (no vídeo, no audio) que puedes personalizar en función del momento que estés viviendo en tus relaciones. Para unirte a mi comunidad y recibir el curso, deja tu email en el enlace: https://www.hombrealfa.top/curso-gratis/ *¿Qué aprenderás en este episodio?: 1) El error más común que cometen incluso los hombres casados durante décadas. 2) Por qué una mujer puede quererte... y aun así irse con otro. 3) La verdad biológica que ningún gurú Red Pill se atreve a decirte. 4) Cómo cambia el deseo femenino según su ciclo menstrual (y por qué deberías saberlo). 5) Qué debes entender (y desaprender) para elegir una relación monógama desde tu marco. En este episodio desenmascaramos uno de los mayores tabúes que existen hoy sobre las mujeres: su estrategia reproductiva dual. ¿De verdad buscan al chico malo solo cuando son jóvenes? ¿Y qué pasa cuando se casan? ¿Cambian realmente sus preferencias? Vamos a tirar abajo décadas de cuentos femeninos y falsas Red Pill basándonos solo en biología evolutiva y estudios reales. Porque si no entiendes la hipergamia desde la raíz, acabarás como tantos hombres: perdido, traicionado y sin saber qué ha fallado. PD. Recibe tu curso gratis aquí: https://www.hombrealfa.top/curso-gratis/

Michael Jordan never won an NBA championship until he was paired with the right coach. Then, he won six. Could working with a coach change your MS journey? In this week's episode, health & wellness coach Amy Behimer explains what health coaching is all about and how working with a coach might impact someone living with MS. We're also sharing study results that show DMTs fail to manage MS-related pain. Then, we'll explain how a common misconception can lead to the wrong outcome for someone with MS. And we'll share study results showing that adhering to the Mediterranean or MIND diet improves cognitive performance among people living with MS. We'll also explain why this study raises as many questions as it seeks to answer. We have a lot to talk about! Are you ready for RealTalk MS??! Thank you!  :22 This Week: What working with a health coach is all about  1:08 Study results show that disease-modifying therapies don't help manage MS-related pain (But are they supposed to???)  2:29 Study results show that adhering to the Mediterranean or MIND diet improves cognitive performance among people with MS (Or does it??)  5:13 Health & Wellness Coach Amy Behimer explains how someone living with MS could benefit from coaching  12:11 Share this episode  39:33 Next week's episode  39:53 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/432 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy STUDY: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://www.msard-journal.com/article/S2211-0348(25)00573-5/fulltext STUDY: Mediterranean and MIND Diet Patterns and Cognitive Performance in Multiple Sclerosis: A Cross-Sectional Analysis of the UK Multiple Sclerosis Register https://www.mdpi.com/2072-6643/17/21/3326 JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 432 Guests: Amy Behimer Privacy Policy

Per approfondire gli argomenti della puntata: Altre pillole dedicate all'Età Moderna : https://www.youtube.com/watch?v=04jMzzw0qK4&list=PLpMrMjMIcOkkxE3VRfoFOph9H6S2v2Njr&ab_channel=LaBibliotecadiAlessandria Learn more about your ad choices. Visit megaphone.fm/adchoices

Angel Studios https://Angel.com/HermanJoin the Angel Guild today where you can stream Thank You, Dr. Fauci and be part of the conversation demanding truth and accountability.  Renue Healthcare https://Renue.Healthcare/ToddYour journey to a better life starts at Renue Healthcare. Visit https://Renue.Healthcare/Todd Bulwark Capital https://KnowYourRiskPodcast.comBe confident in your portfolio with Bulwark! Schedule your free Know Your Risk Portfolio review. Go to KnowYourRiskPodcast.com today. Alan's Soaps https://www.AlansArtisanSoaps.comUse coupon code TODD to save an additional 10% off the bundle price.Bonefrog https://BonefrogCoffee.com/ToddThe new GOLDEN AGE is here!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.LISTEN and SUBSCRIBE at:The Todd Herman Show - Podcast - Apple PodcastsThe Todd Herman Show | Podcast on SpotifyWATCH and SUBSCRIBE at: Todd Herman - The Todd Herman Show - YouTubeJenner Furst, director of the latest Angel Studios documentary "Thank You Dr. Fauci" joins the show.Episode Links:Thank You Dr. Fauci | Now Streaming | AngelBREAKING/URGENT: mRNA COVID VACCINES KILLED AT LEAST 10 KIDS, THE FDA REPORTS; An FDA review found the shots to blame for the deaths, FDA's new vaccine chief - Dr. Vinay Prasad - told staffers in an email. The agency will tighten standards on new vaccine approval, Prasad wrote.Fauci's Ebola stuntURGENT: mRNA Covid jabs should NEVER have been approved for children or young adults Pfizer, Moderna, the Biden Administration, and everyone in public health who pushed these for kids and teens have blood on their handsUnmask The Truth | Official Clip | Thank You, Dr. Fauci

What are CEOs across industries doing to build resilience and strong cultures in an age of uncertainty? In this Future of Business series, IdeaCast hosts Alison Beard and Adi Ignatius sat down with four leading CEOs to understand where global business is going. In this episode, host Alison Beard speaks with Noubar Afeyan, the CEO of Flagship Pioneering and Chairman of Moderna. Afeyan shares the organizational models and practices that work best to produce innovation, the difference between managing risk and managing uncertainty, and what separates true breakthrough innovation from everyday, incremental improvements.

“This is a time to reimagine public health and public health/healthcare system integration,” says Dr. Deb Houry, the former chief medical officer for the US Centers for Disease Control and Prevention. In this thoughtful Raise the Line conversation, Dr. Houry reflects on unprecedented federal action in vaccine guidance and other issues since her noteworthy resignation from the CDC in August, and sees a more decentralized landscape emerging where states and localities play a larger role in providing public health recommendations. And while she acknowledges upsides to this shift, she's also concerned what the absence of a national consensus on health standards could mean. “Diseases don't recognize borders, and it's also important that people have equitable access to preventative services, vaccines, and other things,” she tells host Lindsey Smith. Tune in for Dr. Houry's seasoned perspective on this consequential moment in public health, and her encouraging message for learners and early career providers considering a career in the sector.Mentioned in this episode:DH Leadership & Strategy Solutions If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

At the age of 14, Michaela Janssen Pohl became a caregiver for her mother, who lives with MS. I think most of us can agree that just being a teenager carries with it more than enough challenges. Those adolescent years are the years when just about everything in life starts changing. Imagine adding the responsibilities of being a caregiver to all the other things going on in a 14-year-old girl's life. Michaela joins me this week to explain how she found ways to survive and thrive in what can only be described as a challenging situation for any teenager. We'll also explain why you might want to think a little differently about Giving Tuesday this year. We're sharing all the details about the Phase 2 clinical trial focusing on Moderna's investigational Epstein-Barr vaccine and MS (and we'll explain why that might turn out to be important!) We're talking about how MS impacts women's health issues with this year's winner of the Rachel Horne Prize for Women's Research in Multiple Sclerosis, Dr. Kristen Krysko. And we're sharing the results of the Phase 2 clinical trial for PIPE-307, an investigational remyelination therapy. We have a lot to talk about! Are you ready for RealTalk MS??! It's Giving Tuesday (and why that matters more this year than ever before)  :22 This Week: Becoming a caregiver for a parent with MS when you're 14 years old  3:27 A clinical trial focused on an EBV vaccine and MS is recruiting participants  4:25 Dr. Kristen Krysko discusses MS and women's health issues  7:52 Results from the Phase 2 clinical trial for PIPE-307 remyelination therapy  13:48 Michaela Janssen Pohl shares her story of becoming a caregiver at the age of 14  16:55 Share this episode  33:20 Next week's episode  33:40 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/431 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com DONATE: The National MS Society https://nationalmssociety.org/donate SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy PARTICIPATE: Phase 2 Clinical Trial for Moderna's EBV Vaccine and MS https://clinicaltrials.gov/study/NCT06735248 Email: WeCareClinicalTrials@modernatx.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 431 Guests: Dr. Kristen Krysko, Michaela Janssen Pohl Privacy Policy

What does it really take to launch a big idea? One that can change your career, business, or even the world? Is being a visionary enough, or is there a hidden formula for success? Guest Jen Kem says it's all about building the right "unicorn team." But here's the twist: even if you're a solopreneur or running a small business—like me—this book is still for you. Jen's framework isn't about having a massive team; it's about understanding the roles and energies you bring to your work and how to fill in the gaps to achieve success faster and with less burnout.Jen is a brand strategist, entrepreneur, and author of Unicorn Team: The Nine Leadership Types You Need to Launch Your Big Ideas with Speed and Success. With a career working on iconic initiatives for companies like Microsoft, Coca-Cola, and Oracle, she's now revealing how big ideas succeed—not just through visionaries, but through the right mix of leaders who execute and get results.We'll learn how to identify your own leadership type, how even a solo effort can become a "team" by leveraging the right resources, and hear the inspiring story of how a small team at Moderna outpaced industry giants to lead the charge on a life-saving vaccine. Hosted on Acast. See acast.com/privacy for more information.

Unredacted government emails obtained by Senator Ron Johnson show that health officials identified a myocarditis risk from mRNA vaccines months before informing the public. While Pfizer and Moderna were quietly notified, Americans were not. Jefferey Jaxen breaks down the evidence and new studies showing how mRNA and spike proteins affect heart tissue. Del Bigtree calls it a defining moment for accountability in public health.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.